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Abstract    (244 words) 68 
Recently adopted regulatory standards on infant and follow-on formula for the European Union stipulate 69 
that from 2021 onwards, all such products marketed in the European Union must contain 20-50 mg/100 kcal 70 
of omega-3 docosahexaenoic acid (DHA), which is equivalent to about 0.5-1 % of fatty acids and thus higher 71 
than typically found in human milk and current infant formula products, without the need to also include 72 
omega-6 arachidonic acid (ARA). This novel concept of infant formula composition has given rise to concern 73 
and controversy since there is no accountable evidence on the suitability and safety in healthy infants. 74 
Therefore, international experts in the field of infant nutrition were invited to review the state of scientific 75 
research on DHA and ARA, and to discuss the questions arising from the new European regulatory 76 
standards. Based on the available information, we recommend that infant and follow-on formula should 77 
provide both DHA and ARA. The DHA should equal at least the mean content in human milk globally (0.3 % of 78 
fatty acids) but preferably reach a level of 0.5 % of fatty acids. While optimal ARA intake levels remain to be 79 
defined, we strongly recommend that ARA should be provided along with DHA. At current formulas DHA 80 
levels and up to about 0.64%, ARA contents in formulae for infants should at least equal the DHA contents. 81 
Further well-designed clinical studies should evaluate the optimal intakes of DHA and ARA in infants at 82 
different ages based on relevant clinical outcomes. 83 
 .  84 
Key Words: infant nutrition, breast milk substitutes, long-chain polyunsaturated fatty acids (LC-PUFA), 85 
European Commission Formula Delegated Act 2016/127, food safety 86 
 87 
88 
 
5 
 
Introduction 89 
Breastfeeding, which is universally recommended as the optimal choice of infant feeding, always supplies 90 
both the long-chain polyunsaturated fatty acids (LC-PUFA) docosahexaenoic acid (omega-3 [n-3] DHA, 22:6n-91 
3) and arachidonic acid (omega-6 [n-6] ARA, 20:4n-6) (1-3). Many studies have evaluated outcomes in infants 92 
fed infant and follow-on formula containing the n-3 fatty acid DHA at levels from 0.1 to 0.5 % of total fatty 93 
acids together with the n-6 fatty acid ARA, usually with higher ARA levels than those of DHA. Many infant 94 
and follow-on formulas include DHA and ARA close to median worldwide levels of these fatty acids in human 95 
milk (~0.3 and 0.5% of total fatty acids, respectively) (1). Infant formulas with both DHA and ARA have been 96 
widely used worldwide for nearly 20 years without any serious concern for their safety, and benefits have 97 
been reported in some but not in all studies (4-6). In 2016 the European Commission adopted legislation on 98 
Infant and Follow-on Formula in the form of a Delegated Act, which stipulated that by February 2021 all 99 
infant and follow-on formula marketed in the European Union must contain DHA at higher levels than in 100 
currently marketed infant formulas (20-50 mg/100 kcal, approximately 0.5-1% of total fatty acids) without 101 
any requirement for also providing ARA (7). The European legislation also stipulates that the content of the 102 
omega-3 fatty acid eicosapentaenoic acid (EPA, 20:5 n-3) shall not exceed that of DHA, based on the advice 103 
of a preceding opinion paper of the European Food Safety Authority (EFSA) which emphasized that EPA 104 
contents in human milk are low and do not exceed those of DHA (8). The European legislation also rules that 105 
the content of ARA shall not exceed 1% of the total fat content, and the content of all n-6 long-chain 106 
polyunsaturated fatty acids together shall not exceed 2 % of total fat, which is not based on a 107 
recommendation of EFSA (9) but on the previous European Directive on infant and follow-on formula 108 
adopted in 2006 (10). Following the new regulation, the first commercial formula products with high 109 
contents of DHA and without ARA have been recently introduced in Europe.  110 
This novel concept of infant formula composition proposed by the recent European legislation, with 111 
relatively high mandatory contents of DHA but no need to provide ARA, has raised considerable concern and 112 
controversy because there is no accountable documentation of the suitability and safety of this new 113 
approach (11-14).   114 
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Therefore, the charitable Child Health Foundation (Stiftung Kindergesundheit, www.kindergesundheit.de), in 115 
collaboration with the European Academy of Paediatrics (www.eapaediatrics.eu), invited experts in this area, 116 
including previous members of the NDA panel of EFSA and of the EFSA Working Group on Dietetic Products 117 
involved in the scientific report (9) on which the recent legislation has been based (7), along with 118 
representatives of an international organisation of parents, to review these questions at a workshop held on 119 
24 to 25 May, 2019 at Berg near Munich, Germany. Here we report our key considerations and conclusions. 120 
  121 
Previous guidance on DHA and ARA supply in infancy 122 
Several bodies have provided recommendations on the desirable intakes of DHA and ARA in infancy and 123 
early childhood, based on reviews of the existing evidence. Consistent across these bodies was consensus in 124 
recommending the provision of both DHA and ARA, and for the content of DHA not to exceed the content of 125 
ARA. For example, a joint report of the Food and Agriculture Organisation of the United Nations and the 126 
World Health Organisation concluded there is convincing evidence to define adequate intakes for ARA of 0.2-127 
0.3 % of energy intake (E%, about 11-33 mg ARA/100 kcal), and for DHA of 0.10-0.18 E% (about 11-20 mg 128 
DHA/100 kcal) (15). The Health Council of the Netherlands set an adequate daily intake for ARA of 40 mg/kg 129 
bodyweight (bw) and for DHA of 20 mg/kg bw for infants aged 0 to 5 months (16). The French Food Safety 130 
Agency set an adequate intake for ARA of 0.5 % of total fatty acids (about 24 mg ARA/100 kcal), and of DHA 131 
of 0.32 of total fatty acids (about 16 mg DHA/100 kcal) for infants aged 0 to 6 months (17). In 2013, EFSA 132 
defined adequate daily intakes for infants aged 0-6 months as 100 mg DHA and 140 mg ARA, while 100 mg 133 
DHA was recommended for the age range of 6-24 months and 250 mg DHA + EPA at the age range of 24-36 134 
months (8).  135 
In 2009 EFSA concluded that a cause and effect relationship has been established between the intake of 136 
infant  and follow-on formula supplemented with DHA  at  levels  around  0.3%  of  total  fatty  acids  and  137 
visual  function  at  12  months  in  in term infants fed formula up to 12 months, including breastfed infants 138 
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fed formula after weaning up to 12 months, and it recommended that a health claim should be adopted with 139 
the wording “DHA  contributes  to  the  visual development of infants” (18).  140 
With respect to the composition of infant formula, the previous European legislation on infant and follow-on 141 
formula stipulated the optional inclusion of DHA and ARA provided that the content of DHA does not exceed 142 
that of ARA (10). A further requirement was that EPA content does not exceed DHA content, and total n-3 143 
and n-6 LC-PUFA contents do not exceed 1% and 2% of total fat content, respectively (10). Similarly, the 144 
global Standard of the Codex Alimentarius Commission of the Food and Agriculture Organisation of the 145 
United Nations and the World Health Organisation on infant formula and formulas for special medical 146 
puposes intended for infants stipulates the optional inclusion of DHA in infant formula, provided that ARA 147 
reaches at least the same concentration as DHA, while EPA should not exceed the DHA content (19).  148 
Similar conclusions were drawn by international expert groups who advised that infant formula for infants 149 
born at term should provide 0.2-0.5 % of fatty acids as DHA along with at least the same contents of ARA 150 
(20), or at least 0.3 % of fatty acids as DHA along with ARA (21). An expert group advising the Codex 151 
Alimentarius Committee on Nutrition and Foods for Special Dietary Uses (CCNFSDU) concluded that optional 152 
addition of DHA should not exceed levels of 0.5% of total fat intake which has not been documented to be 153 
safe in clinical trials in healthy infants, and ARA contents should reach at least the DHA contents, whereas 154 
the EPA in infant formula should not exceed the DHA content (22). It also emphasized that there is no 155 
sufficient documentation of the benefits and safety of the addition of DHA to infant formula at levels above 156 
0.5% of total fat content, or of DHA without concomitant addition of ARA; such formula composition was 157 
therefore expressively discouraged (22). 158 
In conclusion, these previous guidance documents support the provision of both DHA and ARA to infants, 159 
with intakes of ARA reaching at least those of DHA. Some of these reports also emphasized that metabolism 160 
and fatty acid needs during infant development are uniquely different from adult principles, and that 161 
knowledge of the metabolism and roles of these fatty acids in adults should not be directly extrapolated to 162 
infants.  163 
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In contrast to these reports, an EFSA scientific opinion published in 2014 (9) concluded that DHA should be 164 
added to infant and follow-on formulae in amounts similar to those provided to breast fed infants and 165 
meeting the adequate intake of 100 mg/day previously established by EFSA, but it considered the provision 166 
of ARA unnecessary even in the presence of DHA, even though only one year before EFSA had set the 167 
adequate daily ARA intake for infants in the first half year of life as 140 mg (8).   168 
 169 
ARA supply during development 170 
We reviewed the sources of ARA available to the developing fetus and infant from placental uptake and 171 
transfer from the mother, and from postnatal consumption of human milk. DHA and ARA are preferentially 172 
supplied to the fetus compared to other fatty acids in the maternal circulation; however, ARA transfer, unlike 173 
DHA, apparently is not related to maternal ARA status and intake (23, 24). Similarly, human milk always 174 
supplies both ARA and DHA; in contrast to DHA, the content of ARA in human milk is much less variable and 175 
always near 0.5 % of milk fatty acids, and typically higher than DHA (1-3, 25). We can only speculate about 176 
the physiological relevance of this rather stable ARA provision to the fetus and infant, along with a more 177 
variable DHA supply. It is noteworthy that significant amounts of ARA, along with some other n-6 LC-PUFA, 178 
accumulate in the membranes of organs and tissues. Adrenic acid (ADA, 22:4n-6), an elongation product of 179 
ARA, is a significant component in all membranes studied to date. For example, in brain both n-3 and n-6 LC-180 
PUFA (to an even greater extent) accumulate rapidly in the last intrauterine trimester and exponentially 181 
during the first two years of postnatal life (26, 27). During this period of rapid early development, the ratio of 182 
ADA to ARA in brain continues to increase such that by two  years of age, ADA constitutes nearly half of the 183 
n-6 LC-PUFA in brain, and n-6 LC-PUFA exceed n-3 LC-PUFA content by far (14).  184 
 185 
Possible importance of ARA supply with infant formulas   186 
Several studies have evaluated n-6 LC-PUFA status in infants fed formulas with and without DHA and ARA, 187 
comparing results with those of infants fed human milk. These data demonstrate that both term and 188 
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preterm infants fed formula without ARA have declining ARA status, compared to human milk fed infants. 189 
First reported in 1982, term infant formulas without LC-PUFA resulted in approximately half the amount of 190 
ARA in infant red blood cell (RBC) phosphatidylcholine (PC) (28). Surprisingly, a 3-fold increase in linoleic acid 191 
(18:2n-6) in one of the two infant formulas resulted in the lowest ARA percentage in RBC PC  (28). A recent 192 
study in term infants compared formulas without and with ARA (0 or 34 mg/100 kcal) and DHA (17 mg/100 193 
kcal) and found less than half the amount of ARA (weight%) in plasma of infants fed the formula without 194 
ARA, compared to the formula with ARA (29). Lymphocyte ARA was also affected, and the authors proposed 195 
that ARA supply may have an immunoregulatory role on B-cell activation. The role of ARA in immune 196 
ontogeny is supported by the finding that for every one mol% decline in whole blood ARA in the postnatal 197 
period of preterm infants, there is a 40% increase in the risk of nosocomial sepsis (30). Furthermore, preterm 198 
infants diagnosed with retinopathy of prematurity, a disease characterized by dysregulated immune and 199 
inflammatory responses, demonstrated lower serum ARA levels compared to infants without this diagnosis 200 
(31).  201 
Human milk fed term infants have approximately 75 mg ARA/L in plasma PC shortly after birth, an amount 202 
that is similar in infants born preterm. In preterm infants fed formulas without ARA, the concentration in 203 
plasma PC declines to approximately 40 mg/L and remains low from term corrected age until approximately 204 
6 months later, before gradually increasing over the next 6 months (32). If the formula provides n-3 LCPUFA 205 
(0.2% DHA, 0.3% EPA) without ARA, the plasma PC ARA concentration declines further to approximately 30 206 
mg/L (32). In contrast, preterm infants fed formulas with 0.43% ARA and 0.1% DHA from soon after birth 207 
until 12 months corrected age (CA) have a plasma PC ARA concentration like infants fed human milk during 208 
the same months. These data indicate that the the addition of both LC-PUFAs to infants formulas is 209 
necessary to match circulating levels of DHA and ARA of breastfed infants (13).   210 
ARA availability has been associated with growth of cells in vitro and of human infants in vivo (33, 34). Birth 211 
weight of preterm infants was significantly correlated with plasma ARA contents (34). In preterm infants, 212 
ARA concentration in plasma PC was a significant predictor of normalized weight and length achievement 213 
during the first year of life at all five ages assessed (2, 4, 6.5, 9 and 12 months CA); and higher PC ARA 214 
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predicted larger head circumference at 2 and 4 months CA (35). The two highest quartiles of plasma PC ARA 215 
were associated with infant weight and length achievement near the 50th percentile for term infants, 216 
whereas infants in the two lower quartiles achieved mean weight and length gains that were one standard 217 
deviation lower (35). In another randomized controlled trial (RCT) in 194 premature infants given preterm 218 
formula with no DHA or ARA, with 0.15% energy DHA, or with 0.14% DHA + 0.27% ARA, infants fed DHA+ARA 219 
formula gained weight significantly faster than control infants (34.7 vs. 30.7 g/day) (36). The review of 220 
review of 32 randomized studies, 13 in preterm infants and 19 in term infants, indicate that the suppl,y of n-221 
3 LC-PUFA without n-6 LC-PUFA can reduce growth achievement in preterm and term infants, although the 222 
reported effect sizes are often modest (37). 223 
While there is no conclusive evidence from RCTs in infants born in term comparing effects of formula feeding 224 
without and with ARA on infant growth, the available data suggest that dietary ARA supply may be a relevant 225 
modulator of physiological growth in infancy.   226 
 227 
Impact of genetic variability  228 
Common variants in the fatty acid desaturase (FADS) gene cluster modify the activity of polyunsaturated 229 
fatty acid (PUFA) desaturation and the composition of human blood and tissues lipids (38). FADS 230 
polymorphisms show large effect sizes on plasma and tissue levels of ARA and other n-6 PUFA, whereas 231 
there are only small and in most studies non-significant effects on DHA and other n-3 PUFA (39). Infants with 232 
genetic FADS variants predicting a low activity of the delta-5 and delta-6 desaturating enzymes comprise 233 
about one quarter of the infant population in Europe, but about two thirds to three quarters of infants in 234 
Asia and Latin America (40). In these infants with genetically determined low desaturase activity, ARA 235 
synthesis is ineffectice, therefore they develop particularly low plasma ARA levels without a dietary supply of 236 
preformed ARA (41). Genetic FADS variants are also associated with important health related outcomes such 237 
as plasma lipid concentrations, eczema, and cognitive function (39). Studies on variations in the FADS gene 238 
cluster provide impressive indications for marked gene-diet interactions in the modulation of complex 239 
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phenotypes such as eczema, asthma and cognition, with some studies indicating that breastfeeding 240 
providing both preformed ARA and DHA reduced asthma risk and imporved cognitive outcomes in those 241 
infants with a genetically determined low formation of LC-PUFA (39). Given that genetic FADS variants 242 
influence primarily the formation of ARA and other n-6 LC-PUFA and have only little effect on DHA and other 243 
n-3 LC-PUFA, it appears likely that the provision of preformed ARA with breastfeeding is important for 244 
asthma risk reduction and improved cognitive development at least in infants with genetically low ARA 245 
synthesis. Due to the major differences in genotype distribution and PUFA metabolism, it seems 246 
inappropriate to extrapolate PUFA effects observed in infant populations with predominantly European or 247 
African genotypes to populations with genetically more frequent low desaturase activities, such as in Asian 248 
and Latin American populations. 249 
 250 
How much ARA do infants and young children receive from food? 251 
A review of the worldwide dietary supply of DHA and ARA shows wide variability of intakes, with particularly 252 
low dietary DHA and ARA intakes found in some studies in lower income countries (42, 43). The estimated 253 
daily dietary intake of ARA from food in infants older than 6 months and in young children evaluated in 76 254 
countries of the developing world was 65 mg/day, with the major part provided by human milk. In this study, 255 
the lowest tertile for ARA intake has a higher prevalence of childhood stunting and higher infant mortality 256 
(43). Infants in the US KUDOS cohort had median ARA intakes from food of only 4 and 20 mg/day, 257 
respectively, at 9 (n=190) and 12 (n=201) months of age (S. Carlson, personal communication, 2019). Belgian 258 
preschool children had a mean ARA intake of only 17 mg/day (44). It is evident that infants will not achieve 259 
the adequate dietary intake of 140 mg/day as set by EFSA (8) unless they are fed human milk or an infant 260 
formula providing ARA.  261 
 262 
Ratio of DHA to ARA in formula influences n-6 LC-PUFA in brain and appears to have functional 263 
consequences 264 
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Effects of adding DHA and ARA to infant formula on neurodevelopmental outcomes have been described in 265 
some but not in other studies (4). Infant formulas with different amounts of DHA and ARA were evaluated in 266 
both baboons and human infants, including formulas without LC-PUFA, or with both ARA (~0.7% of total 267 
fatty acids or ~34 mg/100 kcal) and different DHA levels, providing DHA to ARA ratios of 0.5:1 and 1.5:1 (45, 268 
46). Human infants also received a fourth formula with a DHA to ARA ratio of 1:1 (46). Brain n-3 and n-6 269 
LCPUFA were measured in various organs and brain regions in baboon infants (45). In baboons, plasma and 270 
RBC ARA increased in both the LCPUFA-containing formulas; however, the increase was smaller at a DHA to 271 
ARA ratio of 1.5:1. The highest ratio of DHA to ARA (1.5:1) induced a decrease in brain contents of ARA as 272 
well as in n-6 ADA and n-6 docosapentaenoic acid (DPA, 22:5n-6), with DPAn-6 showing the greatest 273 
decrease. 274 
Human infants fed the formula with a DHA to ARA ratio of 1.5:1, like baboon infants, also showed a decrease 275 
in red blood cell ARA, with levels more similar to the group fed formula with no LC-PUFA (47). Cognitive tests 276 
of these four groups of infants up to 9 years of age showed a similar pattern, with less favourable outcomes 277 
in infants randomized to a formula with a high DHA to ARA ratio: the group fed the 1.5:1 ratio of DHA to ARA 278 
generally performed less well than the other two supplemented groups (46). On sustained attention in the 279 
first year of life, a test of rule learning requiring inhibition between 3 and 5 years, and on verbal IQ at 5 and 6 280 
years of age, the children fed formulas with a DHA to ARA ratio of 0.5:1 and 1:1, but not the group fed a ratio 281 
of 1.5:1, performed significantly better than the no LCPUFA group. Brain evoked response potentials to a test 282 
of inhibition (Go-No Go task) at 5.5 years and brain imaging studies at 9 years were consistent with these 283 
results (48, 49).   284 
While the study did not include a group that received DHA without ARA, these results show that a formula 285 
providing nearly 1% DHA and close to 0.7% ARA - and thus less ARA than DHA - was generally ineffective  286 
compared to formulas providing at least as much ARA as DHA. These data reinforce the concern about the 287 
safety of feeding infants high levels of DHA without providing adequate amounts of ARA.   288 
 289 
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Parents’ expectations 290 
Representatives of the parent organization European Foundation for the Care of Newborn Infants (EFCNI) 291 
emphasized that feeding their babies is one of the fundamental tasks for all parents; it is necessary to sustain 292 
life and it is necessary to support optimal growth and development. Too often parents are judged by the 293 
success or otherwise of their ability to feed their child and the process of feeding. The decisions surrounding 294 
the task can be a source of enormous stress for mothers and fathers alike. 295 
Todays parents are better educated, better informed and have a greater understanding of the importance of 296 
the first 1000 days of an infant’s life for long-term outcomes. While the decision to breastfeed or not may 297 
depend on circumstances or choice, the expectations regarding the choice of an infant formula are the same. 298 
Every parent wants to keep their child safe and protect them from harm. As formulas for infants are the only 299 
processed foodstuff which must meet all  nutritional requirements of the infant until appropriate 300 
complimentary feeding can be established, it is critical that there is full confidence by all concerned 301 
regarding the purity of the ingredients, the appropriate composition of the formulas, and the expected 302 
health outcomes. Families are often confused about the differences between the various infant formulas 303 
available on the market. The assumption and expectation by families is that the infant formula products on 304 
offer have been thoroughly tested in preclinical and clinical settings. They expect that the decision to modify 305 
formula composition is risk free and strictly regulated by regulatory bodies, that the manufacturing process 306 
is strictly controled and that the industry has learned from the mistakes of the past.   307 
Whilst the above considerations do not take account of the barriers and difficulties faced by researchers in 308 
meeting the expectations of families, it is important that researchers, industry, learned societies and 309 
regulatory bodies strive to meet the parental expectations regarding first infant formula to achieve optimal 310 
health and development outcomes, whilst maintaining the highest standard of safety.  311 
 312 
Conclusions  313 
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The new European regulation on infant and follow-on formulae (7) stipulates that ingredients other than 314 
those covered by the regulation may only be added to infant or follow-on formulae if the suitability and 315 
safety of such additions have been demonstrated by appropriate studies, following the guidance of scientific 316 
experts (50-54). The authors fully agree with this principle; however, in addition they also strongly support 317 
that other major modifications of the composition of infant or follow-on formulae that have no documented 318 
history of safe use need to be scientifically evaluated in pre-clinical and generally also in clinical studies. The 319 
need for such evaluation is underlined by the tragic experience of induction of severe adverse health effects 320 
in infants fed formula with modified composition without the addition of any new ingredients, e.g. due to 321 
reduced contents of sodium chloride or of thiamine that both lead to serious adverse effects on health and 322 
brain development (55-57).  323 
The European regulation on infant and follow-on formulae (7) proposes a novel composition with mandatory 324 
content of relatively high DHA concentrations (20-50 mg/100kcal, equivalent to about 0.5-1 % of fatty acids) 325 
but no requirement to provide ARA. This novel infant formula composition has not been evaluated in infants 326 
born at term, and there is no accountable data to document the suitability and safety of this novel concept 327 
of infant formula composition in healthy infants. This proposed formula composition deviates markedly both 328 
from the usual composition of human milk, which has never been found to provide DHA without ARA, and 329 
from the composition of formula with added LC-PUFA as evaluated in many clinical trials and as used for 330 
about two decades in Europe and in many other countries around the world. Moreover, studies reviewed 331 
above indicate that the provision of high DHA intakes without balanced amounts of ARA may induce 332 
undesirable effects in infants, such as reduced ARA levels in brain tissue, suboptimal neurodevelopment and 333 
potentially also adverse effects on growth and immune development (58). Under conditions where scientific 334 
evidence cannot resolve uncertainty regarding possible risks for exposed populations, the precautionary 335 
principle is applied to prevent harm (59, 60). Therefore, we recommend that infants should not be fed 336 
formula with high DHA contents but without ARA unless a thorough evaluation of this novel approach has 337 
been performed and evaluated by independent scientific experts. 338 
 339 
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Recommendations for the composition of infant and follow-on formula 340 
Based on the available information, we recommend that all infant formula and follow-on formula should 341 
provide both DHA and ARA. The DHA content in formulae for infants should equal at least the mean content 342 
in human milk globally (0.3 % of fatty acids) but preferably reach a level of 0.5 % of fatty acids, equivalent to 343 
the mean + 1 SD content in human milk globally (1), to cover higher needs of some subgroups of infants, for 344 
example due to variation in genes encoding enzymes mediating polyunsaturated fatty acid metabolism. This 345 
level of 0.5 % DHA is also equivalent to intakes reported to provide functional benefit in several clinical 346 
studies (61). While the minimal or optimal intake levels of ARA in infancy remain to be defined, and current 347 
evidence does not allow determining an optimal ratio of ARA to DHA in the infant diet, we strongly 348 
recommend that ARA should be provided along with DHA. At current formulas DHA levels up to about 0.64% 349 
(47) we support the recommendation of the Codex Alimentarius that ARA contents in formulae for infants 350 
should be at least equal to the contents of DHA (19).   351 
Breast milk DHA in high fish-eating regions such as Japan may contain more than 1% DHA. Formulas that 352 
replicate these higher DHA levels and with ARA levels above 0.7% ARA have not been tested; these should be 353 
clinically evaluated prior to market introduction. Well-designed clinical studies should evaluate the optimal 354 
intakes of DHA and ARA in infants at different ages based on relevant clinical outcomes, such as safety, 355 
growth, neurodevelopment, and immune development. The second half of the first year of life deserves 356 
specific attention since common weaning foods during this period generally provide only small amounts of 357 
DHA and ARA.  We recommend investment of public research funding to enable the execution of adequately 358 
designed and powered clinical studies. 359 
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